医療診断における人工知能（AI）市場：コンポーネント（ソフトウェア、サービス）、アプリケーション（生体内、放射線、神経、CT、MRI、X線、IVD）、エンドユーザー（病院、画像診断センター、診断ラボ）別 - 2027年までの世界市場予測

Artificial Intelligence (AI) in Medical Diagnostics Market by Component (Software, Service), Application (In Vivo, Radiology, Neurology, CT, MRI, X - ray, IVD), End User (Hospital, Diagnostic Imaging Center, Diagnostic Laboratory) - Global Forecast to 2027

医療診断におけるAIの世界市場は、2022年の10億米ドルから2027年には55億米ドルに達し、予測期間中に39.9%のCAGRで推移すると予測されています。医療診断におけるAIの採用は、AIベースの技術の導入を促進するため... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2022年10月5日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	173	165	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

医療診断におけるAIの世界市場は、2022年の10億米ドルから2027年には55億米ドルに達し、予測期間中に39.9%のCAGRで推移すると予測されています。医療診断におけるAIの採用は、AIベースの技術の導入を促進するための様々な政府のイニシアチブの増加、作業負荷を軽減するための放射線科医によるAIソリューションの利用増加、ビッグデータの流入、AIベースのスタートアップに提供される資金、業界を超えたパートナーシップとコラボレーションの増加などの要因によって速いペースで成長している。

しかし、訓練されたAI労働力の不足、不安定な規制、これらのソリューションの採用に対する医療従事者の消極性は、市場成長を抑制する要因になると予想されます。

"ソフトウェア部門は予測期間中に最も高い成長率を示すと予想される"
医療診断におけるAI市場は、コンポーネントベースで、ソフトウェアとサービスに区分される。2021年には、サービス分野が市場を支配し、ソフトウェア分野は予測期間中に高いCAGRで成長すると推定される。ソフトウェアソリューションは、人手不足や画像スキャン量の増加といった課題にもかかわらず、医療機関が競争力を獲得することを支援します。

"医療診断におけるAIの世界市場において、生体内診断セグメントが最大のシェアを占める"
医療診断におけるAI市場は、アプリケーションに基づいて、in vivo診断とin vitro診断に区分されます。2021年にこの市場で最大のシェアを占めたのは、in vivo診断セグメントであった。このセグメントの大きなシェアは、これらのソリューションが一貫してヒューマンエラーの削減と治療効果の向上に役立つため、開業医によるAIソリューションの取り込みが増加していることに起因している可能性があります。

"病院セグメントは、予測期間中に最も高いCAGRで成長すると予想される"
医療診断におけるAI市場は、エンドユーザーに基づいて、病院、画像診断センター、診断研究所、およびその他のエンドユーザーに区分されます。病院セグメントは、2021年にこの市場の最大のシェアを指揮しました。このセグメントの大きなシェアは、病院で行われる画像診断治療手順の数の増加、放射線科患者ワークフローの自動化とデジタル化に傾く病院、患者ケアの質を向上させるための病院での低侵襲手順の採用の増加、ワークフロー改善のための高度画像モダリティの適用の増加に起因するものであると考えられる。
"2021年、医療診断市場のAIは北米が支配する"
2021年、北米が最大の市場シェアを占めました。しかし、アジア太平洋地域は予測期間中に42.6%の高いCAGRを記録すると予測されます。アジア太平洋市場の高い成長率は、主に企業が新興市場で採用している成長戦略、高設備の医療診断インフラ、老人人口の増加、癌の有病率の上昇、政府の有利なイニシアチブの実施に起因している可能性があります。

供給側の一次面接の内訳、企業タイプ別、呼称別、地域別。
- 企業タイプ別企業タイプ別：Tier1 (40%)、Tier2 (30%)、Tier3 (30%)
- 役職別Cレベル(27%)、ディレクターレベル(18%)、その他(55%)
- 地域別北米 (40%)、欧州 (20%)、アジア太平洋 (30%)、RoW (10%)

本市場における主なプレイヤーは、Microsoft（米国）、NVIDIA（米国）、IBM（米国）、Intel Corporation（米国）、Google, Inc.(米国）、Prognos Health（米国）、Nanox AI（イスラエル）、Viz.ai, Inc（米国）、Quibin（スペイン）、Qure.ai（インド）、Therapixel（フランス）、Aidoc（イスラエル）、Koninklijke Philips N.V.（オランダ）、Lunit．Inc.（韓国）、EchoNous Inc.

調査対象範囲
- 本レポートでは、医療診断市場におけるAIをコンポーネント、アプリケーション、エンドユーザー、地域別に調査し
- 市場成長に影響を与える要因（ドライバー、阻害要因、機会、課題など）を分析しています。
- ステークホルダー向けに市場の機会や課題を評価し、市場リーダー向けに競争環境の詳細を提供しています
- 医療診断市場の成長動向、展望、AI全体への貢献に関して、ミクロ市場を調査しています。
- 5つの主要地域に関して、市場セグメントの収益を予測しています。

レポート購入の主なメリット

本レポートは、この市場のリーダー/新規参入者が、市場全体とサブセグメントの収益数値の最も近い近似値に関する情報を得るのに役立ちます。本レポートは、利害関係者が競争環境を理解し、より良いビジネスの位置づけと適切な市場参入戦略を計画するためのより多くの洞察を得るのに役立ちます。また、本レポートは、医療診断市場におけるAIの鼓動を理解し、主要な市場促進要因、阻害要因、課題、機会に関する情報をステークホルダーに提供します。

ページTOPに戻る

1 INTRODUCTION 24
1.1 STUDY OBJECTIVES 24
1.2 MARKET DEFINITION 24
1.3 INCLUSIONS & EXCLUSIONS 25
1.3.1 INCLUSIONS AND EXCLUSIONS 25
1.4 MARKETS COVERED 26
FIGURE 1 AI IN MEDICAL DIAGNOSTICS MARKET SEGMENTATION 26
1.4.1 YEARS CONSIDERED 26
1.5 CURRENCY CONSIDERED 27
1.6 LIMITATIONS 27
1.6.1 SCOPE-RELATED LIMITATIONS 27
1.6.2 METHODOLOGY-RELATED LIMITATIONS 27
1.7 STAKEHOLDERS 27
1.8 SUMMARY OF CHANGES 28
2 RESEARCH METHODOLOGY 29
2.1 RESEARCH DATA 29
FIGURE 2 RESEARCH DESIGN 29
2.1.1 SECONDARY DATA 30
2.1.1.1 Key data from secondary sources 30
2.1.2 PRIMARY DATA 31
FIGURE 3 PRIMARY SOURCES 32
2.1.2.1 Key industry insights 32
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 33
2.2 MARKET SIZE ESTIMATION 33
FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 33
FIGURE 6 MARKET SIZE ESTIMATION 34
TABLE 1 FACTOR ANALYSIS 35
FIGURE 7 AI IN MEDICAL DIAGNOSTICS MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022–2027) 36
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 37
FIGURE 9 TOP-DOWN APPROACH 37
2.3 MARKET DATA ESTIMATION AND TRIANGULATION 38
FIGURE 10 DATA TRIANGULATION METHODOLOGY 38
2.4 STUDY ASSUMPTIONS 39
2.5 RISK ASSESSMENT 39
TABLE 2 RISK ASSESSMENT: AI IN MEDICAL DIAGNOSTICS MARKET 39
3 EXECUTIVE SUMMARY 40
FIGURE 11 AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2022 VS. 2027 (USD MILLION) 40
FIGURE 12 AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 41
FIGURE 13 AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 41
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF AI IN MEDICAL DIAGNOSTICS MARKET 42
4 PREMIUM INSIGHTS 43
4.1 AI IN MEDICAL DIAGNOSTICS MARKET OVERVIEW 43
FIGURE 15 RISING VOLUME OF DIAGNOSTIC IMAGING PROCEDURES AND INFLUX OF BIG DATA TO DRIVE MARKET 43
4.2 NORTH AMERICA: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION AND COUNTRY (2021) 44
FIGURE 16 IN VIVO DIAGNOSTICS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICA IN 2021 44
4.3 AI IN MEDICAL DIAGNOSTICS MARKET SHARE, BY APPLICATION, 2022 VS. 2027 44
FIGURE 17 IN VIVO DIAGNOSTICS TO CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD 44
4.4 AI IN MEDICAL DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 45
FIGURE 18 ASIA PACIFIC REGION TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 45
5 MARKET OVERVIEW 46
5.1 INTRODUCTION 46
FIGURE 19 AI IN MEDICAL DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 46
5.1.1 DRIVERS 47
5.1.1.1 Influx of big data 47
5.1.1.2 Growing number of cross-industry partnerships & collaborations 47
5.1.1.3 Increasing demand for AI-based solutions to reduce work pressure on radiologists 48
5.1.1.4 Rising government initiatives to drive AI-based technologies 48
5.1.1.5 Availability of funding for AI-based startups 49
5.1.2 RESTRAINTS 49
5.1.2.1 Reluctance among medical practitioners to adopt AI-based technologies 49
5.1.2.2 Inadequate AI workforce and ambiguous regulatory guidelines for medical software 50
5.1.3 OPPORTUNITIES 50
5.1.3.1 Untapped emerging markets 50
5.1.3.2 Growing potential of AI in imaging diagnostics for COVID-19 51
5.1.3.3 Increasing focus on developing human-aware AI systems 51

5.1.4 CHALLENGES 51
5.1.4.1 Budgetary constraints 51
5.1.4.2 Unstructured healthcare data 52
5.1.4.3 Data privacy concerns 52
5.1.4.4 Limited interoperability for AI solutions 52
5.2 VALUE CHAIN ANALYSIS 53
FIGURE 20 AI IN MEDICAL DIAGNOSTICS MARKET: VALUE CHAIN 53
5.3 CASE STUDIES 53
5.3.1 FOCUS ON IMPROVING WORKFLOW EFFICACY AND REDUCING BURDEN ON RADIOLOGISTS 53
TABLE 3 USE CASE 1: REDUCING BURDEN ON RADIOLOGISTS BY DEVELOPING AND TESTING AN AI MODEL TO READ LARGE ULTRASOUND DATA 53
5.3.2 IMPROVED TRIAGE 54
TABLE 4 USE CASE 2: PRECISION DRIVEN HEALTH DEVELOPED ML-MODEL TO IMPROVE WORK TRIAGE OF CARDIOLOGISTS (2019) 54
5.4 ECOSYSTEM COVERAGE 54
FIGURE 21 AI IN MEDICAL DIAGNOSTICS: ECOSYSTEM 54
5.5 TECHNOLOGY ANALYSIS 55
TABLE 5 TECHNOLOGICAL DEVELOPMENTS BY LEADING VENDORS 55
5.6 REGULATIONS 56
5.6.1 HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT OF 1996 (HIPAA) 56
5.6.2 HEALTH INFORMATION TECHNOLOGY FOR ECONOMIC AND CLINICAL HEALTH ACT OF 2009 (HITECH) 56
5.6.3 CONSUMER PRIVACY PROTECTION ACT OF 2017 56
5.6.4 NATIONAL CYBERSECURITY PROTECTION ADVANCEMENT ACT OF 2015 56
5.6.5 FUTURE OF LIFE INSTITUTE’S ASILOMAR AI PRINCIPLES 56
5.6.6 THE EUROPEAN MEDICAL DEVICES REGULATION (EU) 2017/745 AND IN-VITRO DIAGNOSTIC MEDICAL DEVICES REGULATION (EU) 2017/746, IN COMBINATION WITH GENERAL DATA PROTECTION REGULATION 2016/679 56
5.6.7 CYBERSECURITY LAW OF PEOPLE'S REPUBLIC OF CHINA 57
5.7 PORTER’S FIVE FORCES ANALYSIS 57
TABLE 6 AI IN MEDICAL DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 57
5.8 INDUSTRY TRENDS 58
5.8.1 ARTIFICIAL INTELLIGENCE IN HEALTHCARE 58
5.8.1.1 Key to AI in Healthcare: Data 58
5.8.1.2 AR and MR in Healthcare Settings 58
5.8.1.3 Healthcare Privacy and Security in 2022 58
5.9 PRICING ANALYSIS 59
5.10 KEY CONFERENCES AND EVENTS (2022−2023) 59
TABLE 7 AI IN MEDICAL DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS 59
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA 60
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 60
FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 60
TABLE 8 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR END USERS 60
5.11.2 BUYING CRITERIA 61
FIGURE 23 KEY BUYING CRITERIA FOR END USERS 61
TABLE 9 KEY BUYING CRITERIA FOR END USERS 61
6 ARTIFICIAL INTELLIGENCE IN MEDICAL DIAGNOSTICS MARKET,
BY COMPONENT 62
6.1 INTRODUCTION 63
TABLE 10 AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 63
6.2 SOFTWARE 63
6.2.1 USE OF AI PLATFORMS IN SOFTWARE TO ENHANCE DECISION-MAKING AND SIMPLIFY WORKFLOWS 63
TABLE 11 AI IN MEDICAL DIAGNOSTICS SOFTWARE MARKET, BY REGION, 2020–2027 (USD MILLION) 64
6.3 SERVICES 64
6.3.1 RISING NEED FOR DEPLOYMENT & INTEGRATION OF AI SYSTEMS TO SUPPORT MARKET GROWTH 64
TABLE 12 AI IN MEDICAL DIAGNOSTICS SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 64
7 ARTIFICIAL INTELLIGENCE IN MEDICAL DIAGNOSTICS MARKET,
BY APPLICATION 65
7.1 INTRODUCTION 66
TABLE 13 AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 66
7.2 IN VIVO DIAGNOSTICS 66
TABLE 14 AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION) 66
7.2.1 IN VIVO DIAGNOSTIC APPLICATIONS MARKET, BY SPECIALTY 67
TABLE 15 AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 67
7.2.1.1 Radiology 67
7.2.1.1.1 AI-based diagnostic tools to reduce work pressure on radiologists 67
TABLE 16 AI IN MEDICAL DIAGNOSTICS FOR IN VIVO RADIOLOGY, BY REGION, 2020–2027 (USD MILLION) 68
7.2.1.2 Cardiology 68
7.2.1.2.1 Rising complexities associated with CVD to drive market 68
TABLE 17 AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO CARDIOLOGY, BY REGION, 2020–2027 (USD MILLION) 68
7.2.1.3 Neurology 69
7.2.1.3.1 Increasing prevalence of critical brain disorders to drive market 69
TABLE 18 AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO NEUROLOGY, BY REGION, 2020–2027 (USD MILLION) 69
7.2.1.4 Obstetrics/Gynecology 70
7.2.1.4.1 Rising use of minimally invasive techniques in gynecology procedures to drive market 70
TABLE 19 AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO OBSTETRICS/GYNECOLOGY, BY REGION, 2020–2027 (USD MILLION) 70
7.2.1.5 Ophthalmology 70
7.2.1.5.1 Rising need for early detection & prevention of eye diseases to drive market 70
TABLE 20 AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO OPHTHALMOLOGY, BY REGION, 2020–2027 (USD MILLION) 71
7.2.1.6 Other specialties 71
TABLE 21 AI IN MEDICAL DIAGNOSTICS MARKET FOR OTHER SPECIALTIES, BY REGION, 2020–2027 (USD MILLION) 71
7.2.2 IN VIVO DIAGNOSTIC APPLICATIONS MARKET, BY MODALITY 72
TABLE 22 AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 72
7.2.2.1 Computed tomography 72
7.2.2.1.1 Rising availability of cardiac CT devices enabled with AI solutions to drive market 72
TABLE 23 AI IN MEDICAL DIAGNOSTICS MARKET FOR COMPUTED TOMOGRAPHY, BY REGION, 2020–2027 (USD MILLION) 73
7.2.2.2 X-ray 73
7.2.2.2.1 Innovative AI solutions for x-ray imaging by key players to drive market 73
TABLE 24 AI IN MEDICAL DIAGNOSTICS MARKET FOR X-RAY, BY REGION, 2020–2027 (USD MILLION) 73
7.2.2.3 Magnetic resonance imaging (MRI) 74
7.2.2.3.1 Rising technological advancements to drive adoption of AI in MRI 74
TABLE 25 AI IN MEDICAL DIAGNOSTICS MARKET FOR MAGNETIC RESONANCE IMAGING, BY REGION, 2020–2027 (USD MILLION) 74
7.2.2.4 Ultrasound 74
7.2.2.4.1 Increasing prevalence of ovarian cancer to drive market demand 74
TABLE 26 AI IN MEDICAL DIAGNOSTICS MARKET FOR ULTRASOUND, BY REGION, 2020–2027 (USD MILLION) 75
7.2.2.5 Other modalities 75
TABLE 27 AI IN MEDICAL DIAGNOSTICS MARKET FOR OTHER MODALITIES, BY REGION, 2020–2027 (USD MILLION) 75
7.3 IN VITRO DIAGNOSTICS 76
7.3.1 INCREASING ADOPTION OF POINT-OF-CARE TESTING IN EMERGING ECONOMIES TO SUPPORT MARKET GROWTH 76
TABLE 28 AI IN MEDICAL DIAGNOSTICS FOR IN VITRO DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION) 76

8 ARTIFICIAL INTELLIGENCE IN MEDICAL DIAGNOSTICS MARKET, BY END USER 77
8.1 INTRODUCTION 78
TABLE 29 AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 78
8.2 HOSPITALS 78
8.2.1 INSTALLATION OF ADVANCED AI DIAGNOSTIC IMAGING SOLUTIONS TO DRIVE MARKET 78
TABLE 30 AI IN MEDICAL DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2020–2027 (USD MILLION) 79
8.3 DIAGNOSTIC IMAGING CENTERS 79
8.3.1 GROWING NUMBER OF PRIVATE IMAGING CENTERS TO DRIVE MARKET 79
TABLE 31 AI IN MEDICAL DIAGNOSTICS MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY REGION, 2020–2027 (USD MILLION) 79
8.4 DIAGNOSTIC LABORATORIES 80
8.4.1 RISING SPECIMEN TEST VOLUME TO DRIVE MARKET 80
TABLE 32 AI IN MEDICAL DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 80
8.5 OTHER END USERS 80
TABLE 33 AI IN MEDICAL DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION) 80
9 ARTIFICIAL INTELLIGENCE IN MEDICAL DIAGNOSTICS MARKET, BY REGION 81
9.1 INTRODUCTION 82
TABLE 34 AI IN MEDICAL DIAGNOSTICS MARKET, BY REGION, 2020–2027 (USD MILLION) 82
9.2 NORTH AMERICA 83
FIGURE 24 NORTH AMERICA: AI IN MEDICAL DIAGNOSTICS MARKET SNAPSHOT 83
TABLE 35 NORTH AMERICA: AI IN MEDICAL DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 84
TABLE 36 NORTH AMERICA: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 84
TABLE 37 NORTH AMERICA: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 84
TABLE 38 NORTH AMERICA: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 85
TABLE 39 NORTH AMERICA: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 85
TABLE 40 NORTH AMERICA: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 85
9.2.1 US 86
9.2.1.1 Increasing volume of imaging procedures to drive market growth 86
TABLE 41 US: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 86
TABLE 42 US: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 87
TABLE 43 US: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 87
TABLE 44 US: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 87
TABLE 45 US: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 88
9.2.2 CANADA 88
9.2.2.1 Research grants and improved academics in radiology to drive market growth 88
TABLE 46 CANADA: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 88
TABLE 47 CANADA: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 89
TABLE 48 CANADA: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 89
TABLE 49 CANADA: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 89
TABLE 50 CANADA: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 90
9.3 EUROPE 90
TABLE 51 EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 90
TABLE 52 EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 91
TABLE 53 EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 91
TABLE 54 EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 91
TABLE 55 EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 92
TABLE 56 EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 92
9.3.1 GERMANY 92
9.3.1.1 Rising government support to drive adoption of AI in medical diagnostics 92
TABLE 57 GERMANY: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 93
TABLE 58 GERMANY: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 93
TABLE 59 GERMANY: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 94
TABLE 60 GERMANY: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 94
TABLE 61 GERMANY: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 94
9.3.2 UK 95
9.3.2.1 Increasing number of radiography procedures to drive market growth 95
TABLE 62 UK: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 95
TABLE 63 UK: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 96
TABLE 64 UK: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 96
TABLE 65 UK: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 96
TABLE 66 UK: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 97
9.3.3 FRANCE 97
9.3.3.1 Availability of funding for companies to enhance AI research in medical imaging 97
TABLE 67 FRANCE: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 98
TABLE 68 FRANCE: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 98
TABLE 69 FRANCE: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 98
TABLE 70 FRANCE: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 99
TABLE 71 FRANCE: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 99
9.3.4 ITALY 99
9.3.4.1 Increasing volume of EHRs and EMRs due to rising geriatric population to drive demand for AI solutions 99
TABLE 72 ITALY: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 100
TABLE 73 ITALY: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 100
TABLE 74 ITALY: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 101
TABLE 75 ITALY: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 101
TABLE 76 ITALY: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 101
9.3.5 REST OF EUROPE 102
TABLE 77 REST OF EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 102
TABLE 78 REST OF EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 102
TABLE 79 REST OF EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 103
TABLE 80 REST OF EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 103
TABLE 81 REST OF EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 103
9.4 ASIA PACIFIC 104
FIGURE 25 ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET SNAPSHOT 104
TABLE 82 ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 105
TABLE 83 ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 105
TABLE 84 ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 105
TABLE 85 ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 106
TABLE 86 ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 106
TABLE 87 ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 106
9.4.1 CHINA 107
9.4.1.1 Rising use of AI in clinical decision-making to drive market 107
TABLE 88 CHINA: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 107
TABLE 89 CHINA: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 108
TABLE 90 CHINA: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 108
TABLE 91 CHINA: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 108
TABLE 92 CHINA: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 109
9.4.2 JAPAN 109
9.4.2.1 Presence of strong healthcare infrastructure to drive uptake of advanced AI solutions 109
TABLE 93 JAPAN: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 109
TABLE 94 JAPAN: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 110
TABLE 95 JAPAN: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 110
TABLE 96 JAPAN: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 110
TABLE 97 JAPAN: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 111
9.4.3 INDIA 111
9.4.3.1 Favorable government initiatives for R&D investments to drive market for AI 111
TABLE 98 INDIA: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 112
TABLE 99 INDIA: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 112
TABLE 100 INDIA: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 112
TABLE 101 INDIA: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 113
TABLE 102 INDIA: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 113
9.4.4 REST OF ASIA PACIFIC 113
TABLE 103 REST OF ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 114
TABLE 104 REST OF ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 114
TABLE 105 REST OF ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 114
TABLE 106 REST OF ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 115
TABLE 107 REST OF ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 115
9.5 REST OF THE WORLD 115
9.5.1 RISING INITIATIVES TO STABILIZE HEALTHCARE SYSTEMS TO DRIVE UPTAKE OF AI-BASED TOOLS 115
TABLE 108 REST OF THE WORLD: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 116
TABLE 109 REST OF THE WORLD: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 116
TABLE 110 REST OF THE WORLD: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 116
TABLE 111 REST OF THE WORLD: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 117
TABLE 112 REST OF THE WORLD: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 117
10 COMPETITIVE LANDSCAPE 118
10.1 OVERVIEW 118
10.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN 118
TABLE 113 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS 118
10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 119
FIGURE 26 REVENUE ANALYSIS OF KEY PLAYERS 120
10.4 RANKING OF PLAYERS, 2021 120
FIGURE 27 AI IN MEDICAL DIAGNOSTICS MARKET: RANKING OF KEY COMPANIES (2021) 120
10.5 COMPETITIVE LEADERSHIP MAPPING 121
10.5.1 STARS 121
10.5.2 EMERGING LEADERS 122
10.5.3 PERVASIVE PLAYERS 122
10.5.4 PARTICIPANTS 122
FIGURE 28 AI IN MEDICAL DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING (2021) 123
10.6 COMPETITIVE LEADERSHIP MAPPING (STARTUPS) 124
10.6.1 PROGRESSIVE COMPANIES 124
10.6.2 DYNAMIC COMPANIES 124
10.6.3 RESPONSIVE COMPANIES 124
10.6.4 STARTING BLOCKS 124
FIGURE 29 AI IN MEDICAL DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS (2021) 125
10.7 COMPETITIVE BENCHMARKING 126
TABLE 114 AI IN MEDICAL DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS 126
TABLE 115 AI IN MEDICAL DIAGNOSTICS MARKET: APPLICATION FOOTPRINT OF KEY PLAYERS 126
TABLE 116 AI IN MEDICAL DIAGNOSTICS MARKET: REGIONAL FOOTPRINT OF KEY PLAYERS 127
10.8 COMPETITIVE SCENARIO 127
TABLE 117 AI IN MEDICAL DIAGNOSTICS MARKET: PRODUCT LAUNCHES, 2019–2022 127
TABLE 118 KEY DEALS, JANUARY 2019–JULY 2022 129
11 COMPANY PROFILES 134
11.1 KEY PLAYERS 134
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
11.1.1 MICROSOFT 134
TABLE 119 MICROSOFT: BUSINESS OVERVIEW 134
FIGURE 30 MICROSOFT: COMPANY SNAPSHOT (2021) 135
11.1.2 NVIDIA 138
TABLE 120 NVIDIA: BUSINESS OVERVIEW 138
FIGURE 31 NVIDIA: COMPANY SNAPSHOT 139
11.1.3 IBM 142
TABLE 121 IBM: BUSINESS OVERVIEW 142
FIGURE 32 IBM: COMPANY SNAPSHOT 143
11.1.4 INTEL CORPORATION 146
TABLE 122 INTEL: BUSINESS OVERVIEW 146
FIGURE 33 INTEL: COMPANY SNAPSHOT 147
11.1.5 GOOGLE (SUBSIDIARY OF ALPHABET, INC.) 149
TABLE 123 GOOGLE: BUSINESS OVERVIEW 149
FIGURE 34 GOOGLE: COMPANY SNAPSHOT 150
11.1.6 SIEMENS HEALTHINEERS 152
TABLE 124 SIEMENS HEALTHINEERS: BUSINESS OVERVIEW 152
FIGURE 35 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT 153
11.1.7 GE HEALTHCARE 156
TABLE 125 GE HEALTHCARE: BUSINESS OVERVIEW 156
FIGURE 36 GE HEALTHCARE: COMPANY SNAPSHOT 157
11.1.8 DIGITAL DIAGNOSTICS, INC (FORMERLY KNOWN AS IDX) 159
TABLE 126 DIGITAL DIAGNOSTICS: BUSINESS OVERVIEW 159
11.1.9 XILINX 161
TABLE 127 XILINX: BUSINESS OVERVIEW 161
FIGURE 37 XILINX: COMPANY SNAPSHOT 161
11.1.10 INFORMAI LLC 163
TABLE 128 INFORMAI: BUSINESS OVERVIEW 163
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
11.2 OTHER PLAYERS 164
11.2.1 HEARTFLOW, INC 164
11.2.2 ENLITIC, INC 164
11.2.3 DAY ZERO DIAGNOSTICS, INC 165
11.2.4 AIDENCE 165
11.2.5 BUTTERFLY NETWORK, INC. 166
11.2.6 PROGNOS HEALTH 166
11.2.7 NANOX AI 167
11.2.8 VIZ.AI, INC 167
11.2.9 QUIBIM 168
11.2.10 QURE.AI 169
11.2.11 THERAPIXEL 169
11.2.12 AIDOC 170
11.2.13 KONINKLIJKE PHILIPS N.V. 170
11.2.14 LUNIT. INC 171
11.2.15 ECHONOUS INC. 171
12 APPENDIX 172
12.1 DISCUSSION GUIDE 172
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 175
12.3 CUSTOMIZATION OPTIONS 177
12.4 RELATED REPORTS 177
12.5 AUTHOR DETAILS 178

ページTOPに戻る

Table of Contents

Summary

The global AI in medical diagnostics market is projected to reach USD 5.5 Billion by 2027 from USD 1.0 Billion in 2022, at a CAGR of 39.9% during the forecast period. The adoption of AI in medical diagnostics is growing at a fast pace owing to factors such as rise in various government initiatives to drive the uptake of AI-based technologies, AI solutions being more use by radiologists to reduce workload, the influx of big data, fundings made available for AI-based startups, and the growing number of cross-industry partnerships & collaborations.

However, the lack of trained AI workforce, unstable regulations, and the reluctance among medical practitioners to adopt these solutions are factors expected to restrain the market growth.

“Software segment is expected to grow at the highest rate during the forecast period”
On the basis components, AI in medical diagnostics market is segmented into software and services. In 2021, the services segment dominated the market, while the software segment is estimated to grow at a higher CAGR during the forecast period. Software solutions help healthcare providers gain a competitive edge despite the challenges of being short-staffed and facing increasing imaging scan volumes.

“In Vivo Diagnostics Segment accounted for the largest share of the global AI in the medical diagnostics market”
On the basis of application, AI in the medical diagnostics market is segmented into in vivo and in vitro diagnostics. The in vivo diagnostics segment commanded the largest share of this market in 2021. The large share of this segment can be attributed to the rise in uptake of AI solutions by practitioners, as these solutions consistently help in reducing human errors and improve treatment efficacy.

“The Hospitals segment is expected to grow with the highest CAGR during the forecast period”
On the basis of end users, the AI in the medical diagnostics market is segmented into hospitals, diagnostic imaging centers, diagnostic laboratories, and other end users. The hospitals segment commanded the largest share of this market in 2021. The large share of this segment can be attributed to the growth in number of diagnostic imaging treatment procedures performed in hospitals, the hospitals inclining toward the automation and digitization of radiology patient workflow, rise in the adoption of minimally invasive procedures in hospitals to improve the quality of patient care, and the growth in the application of advanced imaging modalities to improve workflow.
“North America to dominate the AI in the medical diagnostics market in 2021.”
In 2021, North America accounted for the largest market share of this market. However, the Asia Pacific market is projected to register the highest CAGR of 42.6% during the forecast period. The high growth rate of the Asia Pacific market can primarily be attributed to the growth strategies companies are adopting in emerging markets, high facility medical diagnostics infrastructure, rising geriatric population, rise in prevalence of cancer, and the implementation of favorable government initiatives.

Breakdown of supply-side primary interviews, by company type, designation, and region:
• By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
• By Designation: C-level (27%), Director-level (18%), and Others (55%)
• By Region: North America (40%), Europe (20%), Asia Pacific (30%), and RoW (10%)

The prominent players in this market are Microsoft (US), NVIDIA (US), IBM (US), Intel Corporation (US), Google, Inc.(Subsidiary of Alphabet, Inc) (US), Siemens Healthineers (Germany), GE Healthcare (US), Digital Diagnostics, Inc (US), Xilinx (US), InformAI LLC (US), HeartFlow, Inc (US), Enlitic, Inc (US), Day Zero Diagnostics, Inc(US), Aidence (Netherlands), Butterfly Network, Inc. (US), Prognos Health (US), Nanox AI (Israel), Viz.ai, Inc (US), Quibin (Spain), Qure.ai (India), Therapixel (France), Aidoc (Israel), Koninklijke Philips N.V. (Netherlands), Lunit. Inc (South Korea), EchoNous Inc. (US)

Research Coverage
• The report studies the AI in the medical diagnostics market based on component, application, end user, and region
• The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth
• The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders
• The report studies micro-markets with respect to their growth trends, prospects, and contributions to the total AI in the medical diagnostics market
• The report forecasts the revenue of market segments with respect to five major regions

Key Benefits of Buying the Report:

The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the AI in the medical diagnostics market and provides them information on key market drivers, restraints, challenges, and opportunities.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（SaaS（Software as a Service））の最新刊レポート

MarketsandMarkets社のSaaS（Software as a Service）分野での最新刊レポート

本レポートと同じKEY WORD（ai）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（SaaS（Software as a Service））の最新刊レポート

MarketsandMarkets社のSaaS（Software as a Service）分野での最新刊レポート

本レポートと同じKEY WORD（ai）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?